1. Home
  2. PAYS vs ALT Comparison

PAYS vs ALT Comparison

Compare PAYS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysign Inc.

PAYS

Paysign Inc.

HOLD

Current Price

$6.99

Market Cap

375.7M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.61

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYS
ALT
Founded
2001
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.7M
421.5M
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
PAYS
ALT
Price
$6.99
$2.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$9.42
$17.67
AVG Volume (30 Days)
603.8K
2.6M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
85.71
25.37
EPS
0.09
N/A
Revenue
$24,120,434.00
$41,000.00
Revenue This Year
$33.83
N/A
Revenue Next Year
$14.89
N/A
P/E Ratio
$74.33
N/A
Revenue Growth
N/A
105.00
52 Week Low
$3.08
$2.56
52 Week High
$8.88
$7.73

Technical Indicators

Market Signals
Indicator
PAYS
ALT
Relative Strength Index (RSI) 56.41 36.34
Support Level $5.05 $2.56
Resistance Level $8.04 $4.19
Average True Range (ATR) 0.42 0.12
MACD -0.04 -0.03
Stochastic Oscillator 36.76 9.79

Price Performance

Historical Comparison
PAYS
ALT

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: